Clinical trial · Interventional
Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Stereotactic body radiotherapy (SBRT) has emerged as one of the leading curative method for early stage non-small cell lung cancer (NSCLC). However, assessing the status of the disease during post-SBRT follow up presents a challenge. Currently, chest Computed Tomography (CT) is the main technique to detect whether cancer has come back, but this method has demonstrated poor accuracy and reliability in determining if the observed post-operative lung changes are benign or malignant. Positron-emission tomography (PET) is an imaging technique that uses special radioactive tracers to cell growth. The use of PET scans with a tracer that target the pathways of DNA synthesis may be more accurate than CT for detecting if the cancer has come or not. The purpose of this study is to see if a PET radiotracer called 18F-FLT (3'-deoxy-3'-fluorothymidine) can identify cancer recurrences accurately compared to regular CT scans.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer (NSCLC) | Lung Non-Small Cell Carcinoma | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FLT-PET | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- FLT-PET
- description
- 1. Cohort 1: Patients in this cohort would be treatment naïve and will be planned for SBRT treatment according to established institutional practices. FLT-PET in this subgroup will be performed before radiation therapy. 2. Cohort 2: Patients who have had SBRT and demonstrate typical or stable lung fibrosis on follow up CT 3. Cohort 3: Patients who have had SBRT and demonstrate findings suspicious for recurrence on follow up CT or who have biopsy demonstrating disease recurrence.
- interventionNames
- Procedure: FLT-PET
Primary outcomes (1)
- measure
- To report the SUVmax for the three cohorts
- timeFrame
- 1 year
Secondary outcomes (1)
- measure
- To compare FLT uptake in 4D (respiratory sorted) versus free breathing FLT-PET scans
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age ≥ 18 years 2. Must have been treated at or plan to be treated at Princess Margaret Cancer Centre with SBRT for an early-stage NSCLC (T1N0M0; T2N0M0; or T3N0M0 chest wall primary tumours only) and are either: 1. Prior to treatment with lung SBRT (for Cohort 1) 2. Have radiographic findings on that are felt to be related to fibrosis at any time point following lung SBRT 3. Have radiographic findings on CT that are suspicious for recurrence at any time point following lung SBRT 3. Ability to provide written informed consent to participate in the study Exclusion Criteria: 1. Previous systemic therapy 2. Previous thoracic radiotherapy(excluding the index lung SBRT treatment) 3. Active malignancy other than lung cancer 4. Unable to remain supine for more than 30 minutes 5. If taking the drug Antabuse 6. Pregnancy
References
Publications (0)
Data not yet available